Focused On-demand Library for Intraflagellar transport protein 56

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Tetratricopeptide repeat protein 26

Alternative UPACC:

A0AVF1; A4D1S3; B7Z5M0; C9J2N7; F8W724; Q9H9S8; Q9NTC0


Intraflagellar transport protein 56, also known as Tetratricopeptide repeat protein 26, plays a crucial role in the intraflagellar transport (IFT) complex B. This protein is essential for the transport of specific ciliary cargo proteins related to motility and is pivotal in maintaining the integrity of the IFT complex B, ensuring proper ciliary localization of its components. It is not required for IFT complex A ciliary localization or function but is vital for proper microtubule organization within the ciliary axoneme.

Therapeutic significance:

The protein's involvement in Biliary, renal, neurologic, and skeletal syndrome, a ciliopathy with multisystemic manifestations, underscores its therapeutic significance. Understanding the role of Intraflagellar transport protein 56 could open doors to potential therapeutic strategies for treating this complex syndrome, highlighting the importance of targeted research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.